ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects
出版年份 2014 全文链接
标题
ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects
作者
关键词
-
出版物
CLINICAL INFECTIOUS DISEASES
Volume 59, Issue 7, Pages 1032-1037
出版商
Oxford University Press (OUP)
发表日期
2014-06-19
DOI
10.1093/cid/ciu477
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- HIV-1-Related Central Nervous System Disease: Current Issues in Pathogenesis, Diagnosis, and Treatment
- (2013) S. Spudich et al. Cold Spring Harbor Perspectives in Medicine
- Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid
- (2012) David Croteau et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Higher CNS Penetration-Effectiveness of Long-term Combination Antiretroviral Therapy Is Associated With Better HIV-1 Viral Suppression in Cerebrospinal Fluid
- (2012) Alexia Cusini et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration
- (2012) D. Croteau et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
- (2011) Sherene Min et al. AIDS
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1
- (2010) D. Croteau et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Discordance Between Cerebral Spinal Fluid and Plasma HIV Replication in Patients with Neurological Symptoms Who Are Receiving Suppressive Antiretroviral Therapy
- (2010) Ana Canestri et al. CLINICAL INFECTIOUS DISEASES
- Efavirenz concentrations in CSF exceed IC50 for wild-type HIV
- (2010) B. M. Best et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment
- (2010) Arvid Edén et al. JOURNAL OF INFECTIOUS DISEASES
- HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors
- (2010) Robert K. Heaton et al. JOURNAL OF NEUROVIROLOGY
- HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study
- (2010) R. K. Heaton et al. NEUROLOGY
- Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1–Infected Individuals
- (2009) Aylin Yilmaz et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Raltegravir Cerebrospinal Fluid Concentrations in HIV-1 Infection
- (2009) Aylin Yilmaz et al. PLoS One
- Validation of the CNS Penetration-Effectiveness Rank for Quantifying Antiretroviral Penetration Into the Central Nervous System
- (2008) Scott Letendre ARCHIVES OF NEUROLOGY
- Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection
- (2008) Elizabeth Sinclair et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Antiretroviral Therapy and Central Nervous System HIV Type 1 Infection
- (2008) Richard W. Price et al. JOURNAL OF INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started